Tag Archives: Manufacturing Depression

The New York Times on Psychiatric Disorders, “Not Diseases, but Categories of Suffering”

YOU’VE got to feel sorry for the American Psychiatric Association, at least for a moment. Its members proposed a change to the definition of autism in the fifth edition of their Diagnostic and Statistical Manual of Mental Disorders, one that would eliminate the separate category of Asperger syndrome in 2013. And the next thing they knew, a prominent psychiatrist was quoted in a front-page article in this paper saying the result would be fewer diagnoses, which would mean fewer troubled children eligible for services like special education and disability payments.

Then, just a few days later, another front-pager featured a pair of equally prominent experts explaining their smackdown of the A.P.A.’s proposal to eliminate the “bereavement exclusion” — the two months granted the grieving before their mourning can be classified as “major” depression. This time, the problem was that the move would raise the numbers of people with the diagnosis, increasing health care costs and the use of already pervasive mind-altering drugs, as well as pathologizing a normal life experience.

Fewer patients, more patients: the A.P.A. just can’t win. Someone is always mad at it for its diagnostic manual.

Profiting from mental ill-health

There’s a reason psychiatrists prescribe drugs rather than talking therapy: the latter makes no money for pharmaceutical firms. The New York Times recently led with a front-page splash about psychiatry’s propensity to prescribe pills, “Talk Doesn’t Pay, So Psychiatry Turns Instead to Drug Therapy”. That news is already widely known in the mental health field, but it has vast ramifications for Americans trying to maintain their sanity in our market-driven and medical system for delivering mental healthcare. What does the turn to drug therapy mean for the mass of Americans?

Manufacturing Depression: The secret history of science run amok, a lust for money & the manufacturing of a disease

Gary Greenberg opens his new history of depression with a riveting tale of scientific ingenuity. A young, unknown marine biologist with an interest in mussels happens to discover the neurotransmitter serotonin and helps spur the antidepressant revolution. Lest we get too excited, though, Greenberg deflates our hopes just a few pages in. Great science stories involve chance discoveries that change our everyday lives, he says—but this is not the kind of story he is going to tell.